The House Insurance Committee took up several charges on December 6, 2017, and heard from invited testimony on the Texas health insurance market, network stability and adequacy, waiver programs, balanced and surprise billing, pharmacy benefit managers, and prescription drug formularies. This report contains a summary of that hearing, in addition to a document entitled, "Texas Waiver Options and Implementation Analysis."